Objective-The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)-mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage-activating protein pathway. Approach and Results-Inflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavageactivating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage-activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage-activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress. 
S tatins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R), have revolutionized the treatment of hypercholesterolemia. They trigger a regulatory response that leads to a specific decrease in the concentration of plasma low-density lipoprotein cholesterol (LDL-C) and a reduction in atherosclerotic cardiovascular disease. Statin therapy lowers plasma LDL-C level by 30% to 50% and reduces major coronary events by 27% in the general population. However, ≈20% of patients fail to respond to statins, appearing to be statin resistant. 1 Those with low C-reactive protein levels have better clinical outcomes regardless of the resultant level of LDL-C, 2 suggesting that inflammation may render statins less effective; patients with chronic kidney disease (CKD), diabetes mellitus, and other inflammatory diseases are especially at risk.
Statin administration to patients with CKD is now common; CKD is associated with high plasma C-reactive protein that predicts cardiovascular risk. 3 Previously, the Die Deutsche Diabetes Dialyse (4D) trial, Assessment of Survival and Cardiovascular Events (AURORA) trial in dialyzed patients, 4, 5 and the Assessment of Lescol in Renal Transplantation (ALERT) studies 6 showed no significant reduction in cardiovascular events in the inflamed patients. Nevertheless, statins were associated with the expected reduction in plasma LDL-C in these patients. This seriously questions the value of plasma LDL-C in the assessment of reducing risk in cholesterol lowering in inflamed patients; the biological effect of statins may depend on inhibition of HMGCoA-R activation rather than plasma LDL-C in such patients.
High plasma LDL-C is an established risk factor for atherosclerosis. However, cholesterol homeostasis is disrupted in patients with CKD. We have demonstrated previously that inflammation redistributes circulating cholesterol to peripheral tissues and organs such as the arterial wall and kidney. [7] [8] [9] Such redistribution may lead to an increase in cardiovascular risk in hemodialysis patients and lowering plasma LDL-C level. Hence, plasma LDL-C level alone is an unreliable marker of cardiovascular risk in the context of inflammation. The efficacy of statins is linked more directly to HMGCoA-R activity. 10 It is therefore important to know whether statins can inhibit effectively HMGCoA-R in vessels exposed to inflammatory stress.
The transcriptional activation of HMGCoA-R is controlled via feedback regulation by intracellular cholesterol levels. 11 Sterol regulatory element binding proteins (SREBPs)-1 and -2 are transcription factors for the HMGCoA-R gene and are critical molecules in the feedback system. 12 SREBP cleavageactivating protein (SCAP) is a cholesterol sensor and chaperone of SREBPs that regulates the activity of SREBPs by controlling their subcellular localization. 13 When cells require cholesterol, SCAP shuttles SREBPs from the endoplasmic reticulum (ER) to the Golgi for activation by proteolytic cleavages. The cleaved N-terminal SREBP (nSREBP) fragments increase HMGCoA-R transcription, thereby increasing cholesterol synthesis. When intracellular cholesterol concentration is high, ER cholesterol promotes the binding of SCAP to insulin-induced gene-1 (Insig-1) proteins and facilitates retention of the SCAP/SREBP complex within the ER, inhibiting cholesterol synthesis. This feedback regulation prevents intracellular cholesterol overload.
We hypothesize that inflammation increases HMGCoA-R expression by disrupting SCAP/SREBP2-mediated feedback regulation and promoting de novo synthesis of cholesterol.
Furthermore, increased HMGCoA-R activity in vascular smooth muscle cells (VSMCs) and hepatic cells weakens the inhibitory effect of statin on HMGCoA-R. Conventional low-dose statin treatment might not fully inhibit intracellular cholesterol synthesis, leading to accumulation of lipid in the vessel because of tissue statin resistance, although plasma LDL-C may be reduced.
We therefore investigated the inhibitory effect of atorvastatin on HMGCoA-R activity and its mediated cholesterol synthesis in VSMCs, hepatic cells (HepG2 cells) in vitro. To exclude the involvement of scavenger receptors and specify the role of SCAP/LDL receptor/HMCGoA-R pathway in the effect of statin treatment, apolipoprotein E/scavenger receptors class A/CD36 triple knockout (ApoE/SRA/CD36 KO) mice were used to assess the in vivo effect of inflammation on statin effectiveness and the underlying mechanisms.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Inflammation Increased HMGCoA-R Expression by Increasing SCAP Expression and Translocation From the ER to the Golgi
Cytokines (interleukin [IL]-1β, tumor necrosis factor-α, and IL-6) and lipopolysaccharides were used in cultured VSMCs to induce inflammatory stress. We demonstrated that the inflammatory mediators enhanced HMGCoA-R mRNA ( Figure 1A ) and protein expression ( Figure 1B The effect of inflammation on SCAP and SREBP2 expression was examined. These inflammatory mediators increased SCAP and SREBP2 mRNA expression in VSMCs ( Figure 1C ). LDL-C loading reduced mRNA expression of SCAP, SREBP2, however, all inflammatory cytokines and lipopolysaccharides overrode LDL-induced suppression of mRNA ( Figure 1D ) and protein ( Figure 1E ) expression of SCAP and nSREBP2 (N-terminal SREBP2, an active form from nuclear extract) in VSMCs.
To test the specific roles of SCAP on IL-1β-induced HMGCoA-R expression in cells, SCAP was knocked down by transfection with human SCAP small interfering RNA (SCAPi) or overexpressed by transfection with human SCAP cDNA (O/E SCAP) in VSMCs. The increased mRNA expression of SREBP2 and HMGCoA-R induced by IL-1β in the absence or presence of LDL-C loading was blocked by knocking down SCAP (SCAPi) in comparison with negative control in VSMCs (Figure 2A ). The protein expression of nSREBP and HMGCoA-R by IL-1β was also reduced by knocking down SCAP in VSMCs ( Figure 2B ). The increased SCAP accumulation in the Golgi by IL-1β was blocked by SCAPi in VSMCs ( Figure 2C , II versus I). Interestingly, overexpression of SCAP (O/E SCAP) overrode the inhibitory effect of SCAP accumulation in the Golgi by LDL-C and caused abnormal SCAP accumulation in the Golgi of VSMCs ( Figure 2C , IV versus III). As expected, SCAPi prevented lipid accumulation in VSMCs ( Figure 2D , II versus I), whereas O/E SCAP Figure 2D , IV versus III). These results suggest that SCAP specifically mediated HMGCoA-R expression, activation, and foam cell formation by IL-1β stimulation. HMGCoA-R protein stability was checked by incubating cells with protein synthesis inhibitor cycloheximide for various time points ( Figure 3A ) and the half-life of HMGCoA-R protein was calculated using nonlinear regression analysis. The half-life of HMGCoA-R protein was 3.7 hours in wild-type of VSMCs. SCAPi shortened the half-life of HMGCoA-R protein to 2.3 hours in VSMCs, whereas O/E SCAP increased HMGCoA-R protein half-life to 4.5 hours in VSMCs ( Figure 3B ), suggesting that increased SCAP expression enhanced HMGCoA-R protein stability.
Inflammation Caused Statin Resistance
Furthermore, we investigated the difference of HMGCoA reductase mRNA expression in VSMCs and hepatocytes HepG2 under inflammatory stress. Inflammation increased the mRNA levels of HMGCoA-R 3.48-and 1.98-fold with and without LDL loading in VSMCs, whereas only 1.86-and 1.40-fold with and without LDL loading in hepatocytes ( Figure 4A ). It seems that the degree of increase of HMGCoA-R expression under inflammatory stress in VSMCs is much greater than that in Hepatic cells.
Next, we investigated whether high levels of intracellular cholesterol (associated with high HMGCoA-R activity induced by inflammation) downregulate HMGCoA-R gene expression by monitoring mRNA expression of HMGCoA-R in VSMCs and HepG2 cells. We calculated the concentration of LDL-C required for 50% inhibition of HMGCoA reductase mRNA (IC50 LDL ) in both VSMCs and HepG2 cells using nonlinear regression analysis. LDL dose dependently inhibited HMGCoA reductase mRNA expression in both VSMCs and HepG2 cells but to a greater degree in VSMCs. The IC50 LDL in HepG2 was 80 μg/mL, but it was only 20 μg/ mL in VSMCs ( Figure 4B ), suggesting that a 4× higher concentration of LDL is required to achieve a similar inhibitory effect on HMGCoA-R mRNA expression by feedback regulation in hepatocytes in comparison with VSMCs. This implies that the threshold for HMGCoA reductase gene transcription inhibition in VSMCs is much lower than that in HepG2 cells under the experimental conditions described in this study. We also studied the inhibitory effect of different concentrations of LDL on HMGCoA reductase mRNA in the presence of IL-1β ( Figure 4B ). Inflammatory stress increased IC50 LDL from 20 to 75 μg/mL in VSMCs (3.75-fold) and from 80 to 100 μg/mL (1.25-fold) in HepG2 cells, suggesting that much higher concentrations of cholesterol are required to achieve 50% inhibition on HMGCoA-R expression in the presence of inflammation.
To test whether HMGCoA-R activity induced by inflammatory cytokines impaired the inhibition of HMGCoA-R by statin treatment, the concentration of atorvastatin required for 50% inhibition of HMGCoA-R activity (IC50 statin ) was calculated using nonlinear regression analysis in VSMCs and HepG2 cells. The concentrations of atorvastatin for IC50 statin were 16 and 25 μmol/L in VSMCs and HepG2 in the absence of IL-1β. The same concentrations of atorvastatin in the presence of IL-1β led only 30% inhibition of HMGCoA-R activity in VSMCs and HepG2 ( Figure 4C ). Atorvastatin at 1 and 50 μmol/L significantly reduced HMGCoA-R activity in both cells. However, in the presence of IL-1β, atorvastatin at higher dose (50 μmol/L) has the effect of reducing HMGCoA-R activity in both cells ( Figure 4D ). These results suggested that inflammation not only increases HMGCoA-R activity but also weakens the statin's inhibitory effect on HMGCoA-R (inducing statin resistance) in both cells.
To investigate whether SCAP overexpression results in statin resistance, SCAP was overexpressed in VSMCs. As shown in Figure 5E , 16 μmol/L of atorvastatin (IC50 statin ) resulted in 50% inhibition of HMGCoA-R activity in wildtype cells, but only achieved 20% inhibition of HMGCoA-R activity in O/E SCAP VSMCs. In contrast, the same concentrations (IC50) of atorvastatin achieved up to 65% inhibition of HMGCoA-R activity in SCAPi VSMCs ( Figure 4E ).
Next, the dose dependency of atorvastatin-induced inhibition of intracellular cholesterol levels was demonstrated in wild-type VSMCs. Intracellular cholesterol levels were increased in O/E SCAP cells. Significant reduction of intracellular cholesterol ester level could be achieved from 10 μmol/L of atorvastatin ( Figure 4F ) in wild-type cells. However, much higher concentrations of atorvastatin were required to reduce intracellular cholesterol levels in O/E SCAP cells. These data suggest that overexpression of SCAP causes cholesterol accumulation and statin resistance and a higher dose of statin is required to achieve a similar biological effect in SCAPoverexpressing cells, whereas knocking down of SCAP improves the effectiveness of atorvastatin and reduces lipid accumulation in VSMCs.
In addition, we examined the sensitivities of LDL receptor regulation in VSMCs and HepG2 under inflammatory stress. Inflammation increased the mRNA levels of LDL receptor 1.78-and 1.84-fold with and without LDL loading in VSMCs, whereas 2.56-and 3.31-fold in hepatocytes ( Figure  IA in the online-only Data Supplement), suggesting that LDL receptor in hepatic cells was more sensitive for upregulation under inflammatory stress than in VSMCs. Atorvastatin at 1 and 50 μmol/L significantly increased LDL receptor level in both cell types; however, LDL receptor on the hepatic cells is also more sensitive for upregulation by intracellular cholesterol depletion with atorvastatin treatment in comparison with VSMCs ( Figure IB in the online-only Data Supplement). In the presence of IL-1β, the effect of LDL receptor upregulation by atorvastatin was inhibited significantly. Atorvastatin at higher dose (50 μmol/L) with IL-1β has the equivalent effect of increased LDL receptor at lower dose (1 μmol/L) without IL-1β in hepatic cells ( Figure IB in the online-only Data Supplement). These results suggested that inflammation impaired the upregulation of LDL receptor by atorvastatin treatment.
To confirm the findings from in vitro experiments, a chronic low-grade systemic inflammation was induced in ApoE/SRA/ CD36 KO mice with a combination of a Western diet and daily subcutaneous injection of 10% casein for 14 weeks. The induction of inflammation was confirmed by an increase of serum amyloid A (SAA) and IL-6 in the casein-injected mice compared with controls ( Figure 5A ). Atorvastatin at 2 mg/kg per day significantly reduced serum total cholesterol and LDL-C levels in control mice. However, casein-injected mice required 10 mg/kg per day atorvastatin to reduce serum total cholesterol and LDL-C to the same levels achieved with a dose of 2 mg/kg per day in non-casein-injected mice ( Figure 5B), suggesting that inflammatory stress caused atorvastatin resistance. At the same time SAA and IL-6 were higher in the casein-injected mice given atorvastatin 2 mg/kg per day compared with mice receiving atorvastatin of 10 mg/kg per day ( Figure 5A ), implying that a high dose of statin has an additional anti-inflammatory effect.
Oil Red O staining showed that a Western diet for 14 weeks induced lipid droplet accumulation in the aortic plaques ( Figure 5C and 5D) of the control group of ApoE/SRA/CD36 KO mice and that this was exacerbated by casein injection. Atorvastatin at 2 mg/kg per day reduced lipid accumulation in aortic plaques of noninflamed mice, but it did not reduce lipid droplets in aortic plaques of casein-injected mice. A higher dose of atorvastatin (10 mg/kg per day) was required to achieve an equivalent effect under inflammatory stress.
In addition, casein injection increased mRNA and protein expression of LDL receptor and HMGCoA-R in mouse liver and aorta ( Figure 6A and 6C) . The mRNA levels of LDL receptor were increased 4.56-fold in liver and 2.94-fold in aorta. The mRNA levels of HMGCoA-R were increased 1.49-fold in liver and 2.73-fold in aorta. Atorvastatin at 2 and 10 mg/kg per day significantly increased LDL receptor level. LDL receptor on the livers is also more sensitive for upregulation by atorvastatin treatment in comparison with aorta ( Figure 6D ). Under inflammatory stress, atorvastatin at higher dose (10 mg/kg per day) has the same effect of increased LDL receptor by atorvastatin at 2 mg/kg per day in noninflamed mice ( Figure 6D ). This result suggests that there is a different threshold or sensitivity for LDL receptor and HMGCoA-R regulation in liver and aorta. Inflammation impaired the upregulation of LDL receptor by atorvastatin treatment, which confirms the results from the in vitro study.
Casein injection further increased mRNA expression of SCAP, SREBP, and HMGCoA-R in the aorta of mice receiving atorvastatin of 2 mg/kg per day, but mRNA expression was not further increased in mice receiving atorvastatin of 10 mg/kg per day, again implying that a high dose of statin has an additional anti-inflammatory effect ( Figure 6E ).
Discussion
Current evidence indicates that inflammation plays a central role in the initiation and progression of atherosclerosis and in the thrombotic complications of this disease.
14,15 Recent experimental and clinical evidence has highlighted the fact that inflammatory mediators 14, 16, 17 significantly aggravate foam cell formation, the hallmark of atherosclerosis. 18 Lipid-loaded foam cells have been regarded traditionally as being derived from macrophages. However, it is now known that VSMCs, which highly express SCAP/LDL receptor/HMCGoA-R molecules, can also be converted into foam cells. 19, 20 We have previously published evidence that inflammation increases intracellular cholesterol influx into peripheral tissues such as arterial blood vessels and kidney and decreases cholesterol efflux from these tissues. [7] [8] [9] 21, 22 Inflammatory cytokines, including IL-1β, tumor necrosis factor-α, and platelet-derived growth factor, contribute to lipid deposition and foam cell formation in VSMCs by increasing LDL receptor expression. Because intracellular cholesterol homeostasis is regulated by cholesterol influx, efflux, and de novo cholesterol synthesis, it is important to understand the effects of inflammation on HMGCoA-R-mediated de novo cholesterol synthesis. We have now confirmed this observation in vitro (in both VSMCs and hepatic cells) and have studied the in vivo consequences.
We showed that LDL loading dose dependently inhibited HMGCoA reductase gene transcription in both VSMCs and hepatocytes (HepG2 cells), suggesting that there is an integrated feedback regulation in these cells under normal, noninflamed condition. The IC50 LDL for inhibiting HMGCoA mRNA in VSMCs is 20 μg/mL, which is much lower than 80 μg/mL required for HepG2 cells, indicating that a lower dose of LDL is required to downregulate HMGCoA reductase gene transcription in VSMCs compared with HepG2 cells and that the threshold of HMGCoA-R activity in peripheral cells is lower than that of hepatocytes. However, inflammation abnormally activated HMGCoA-R expression and activity by disrupting the feedback regulation in both cell types as demonstrated in this study. Because the degree of increase in HMGCoA-R activity is much greater in VSMCs in comparison with hepatocytes with a huge capacity for cholesterol synthesis and any excess cholesterol in hepatocytes can be converted into bile salt, it seems likely that the abnormal activation of HMGCoA-R by inflammation may mainly affect peripheral tissues, contributing to foam cell formation.
Statins competitively inhibit HMGCoA-R. The structural similarity and high affinity of the acid form of statin for HMGCoA-R result in specific and effective inhibition of this enzyme. 23 Atorvastatin has rapid oral absorption with an approximate time to maximum plasma concentration of 1 to 2 hours in human. The drug concentrations of 0.01 to 0.1 μmol/L were found in plasma after oral administration of 40 mg atorvastatin. 24 The plasma concentrations are affected by many factors, such as age, food, and concurrent disease. The effective concentrations of statin in plasma are different between human and animals. Metabolites detected after atorvastatin administration indicate that metabolism in the mouse is much more extensive than in humans and other animals. In the mouse, daily doses ranging from 10 to 400 mg/kg per day atorvastatin produced a marked effect on plasma atorvastatin activity at equivalent concentrations, 25 and the dosage of atorvastatin from 1 to 300 mg/kg per day is widely used in many animal studies. 26 Therefore, in this study, atorvastatin was used in a range from 2 to 10 mg/kg per day in vivo and 1 to 50 μmol/L 27-30 in vitro. We also calculated the concentrations of statin which required for 50% inhibition of HMGCoA reductase activity (IC50 statin ) in both VSMCs and HepG2 using nonlinear regression analysis. The concentrations of atorvastatin for IC50 statin were 25 μmol/L in HepG2 and 16 μmol/L in VSMCs. However, the same concentrations of atorvastatin (IC50 statin ) in the presence of IL-1β led to only 30% inhibition of HMGCoA-R activity in HepG2 and VSMCs. This suggests that inflammation weakened the effect of statin on the HMGCoA-R activity and causes statin resistance in both VSMCs and HepG2 cells. In vivo atorvastatin at above effective doses inhibited HMGCoA-R activity and lower plasma LDL-C as expected. However, the enhanced HMGCoA-R expression and activity associated with inflammation weakened the suppressive effects on this enzyme by the atorvastatin, suggesting that inflammation may cause statin resistance. Because inflammation significantly increased HMGCoA-R in peripheral tissues, as discussed above, the statin resistance can be more obvious in peripheral cells in comparison with hepatic cells.
It has been reported that statins have anti-inflammatory properties, which may additionally lead to the vascular protection by unknown mechanisms. In this study, it seems that neither low nor high doses of atorvastatin administration changed IL-6 and SAA levels in the absence of casein injection. However, casein alone significantly increased cytokine levels and atorvastatin dose dependently inhibited cytokines levels, suggesting that atorvastatin has an anti-inflammatory effect once the inflammatory response is activated.
Our previous studies demonstrated that IL-1β increased cholesterol synthesis by the upregulated mRNA and protein expression of HMGCoA-R in VSMCs. 31 This was mediated by the upregulated mRNA expression of SCAP and SREBP2 and the increased translocation of the SCAP/SREBP2 complex from the ER to the Golgi. To investigate whether other inflammatory stimuli have the similar effect on cholesterol homeostasis and the molecular mechanisms involved in the statin resistance under inflammatory stress, we examined the effects of cytokines on SCAP expression and translocation in VSMCs. We showed that LDL-C loading inhibited HMGCoA-R gene transcription, enzyme activity, and cholesterol synthesis in vitro, suggesting an integrated feedback regulation under normal conditions. However, inflammatory stress induced by different inflammatory stimuli (IL-1β, tumor necrosis factor-α, IL-6, and lipopolysaccharides) in cells impaired this regulation by increasing SCAP expression which is consistent with our previous finding in IL-1β. This may result in more SREBP2 trafficking from the ER to the Golgi for activation, enhancing production of more active transcriptional factor nSREBP2 and HMGCoA-R gene transcription. This confirms that inflammation causes an abnormal translocation of SCAP to the Golgi.
The mechanisms by which inflammatory cytokines regulate SCAP gene expression and abnormal translocation are not clear. We have demonstrated previously that knocking down of MyD88 or using I kappa B kinase inhibitor in a human leukemia cell line-1-derived macrophages attenuates the increase of SCAP and its downstream molecules (nSREBP2 and LDL receptor) by inflammation, suggesting a crosstalk between inflammation and SCAP expression pathway. 32 Overexpression of SCAP in vitro caused statin resistance, whereas knocking down SCAP prevented statin resistance induced by inflammatory stress, suggesting that high expression and abnormal Golgi translocation of SCAP could represent the mechanisms for the statin resistance induced by inflammatory stress.
Insigs are key regulators for the activation of HMGCoA-R gene transcription through an association or disassociation with SCAP which regulates the SREBPs/SCAP complex translocation between the ER and the Golgi. Consistent with our previous studies, 31 we demonstrated that inflammatory stress inhibited Insig-1 expression in VSMCs in accordance with inflammatory stress-induced increases of SCAP and HMGCoA-R gene expression, resulting in a significant increase of ratio of HMGCoA-R/Insig-1 in VSMCs ( Figure  IIIA and IIIB in the online-only Data Supplement). It seems that Insig-1 may be present in insufficient concentrations to bind with HMGCoA-R and retain the increased SCAP/ SREBP2 complex in the ER under inflammatory stress, thereby permitting SCAP to move from the ER to the Golgi for HMGCoA-R transcription activation.
The regulation of HMGCoA-R activity at the post-transcriptional level is dependent on protein degradation, which is modulated by SCAP and Insig. Thus, increased SCAP expression enhances HMGCoA-R protein stability, which in turn exacerbates intracellular cholesterol synthesis. In this study, decreased HMGCoA-R degradation was correlated with decreased Insig-1 protein expression by inflammatory stress, suggesting that both SCAP and Insig-1 modulated HMGCoA-R activity at the post-transcriptional level via protein degradation. Both increased transcription and decreased degradation enhance HMGCoA-R expression, activity, and intracellular cholesterol synthesis ( Figure IVA and IVB in the online-only Data Supplement), which contributed to cholesterol accumulation in VSMCs ( Figure IVC and IVD in the online-only Data Supplement), causing statin resistance.
To confirm the results from the in vitro study, we induced inflammation in ApoE/CD36/SRA KO mice, which had been used previously for atherosclerosis studies. Many pathways are involved in foam cell formation, and 2 scavenger receptors type A and type B (CD36) have been strongly implicated in the lipid uptake process. Previous studies showed that SRA and CD36 mediated cholesterol uptake and accumulation in macrophages exposed to oxidized LDL and that mice with deletions of either receptor exhibited marked reductions in atherosclerosis. 33, 34 However, evidence of involvement of scavenger receptors on atherosclerosis is conflicting. Kruth et al 35 have demonstrated that native LDL may transform human macrophages into foam cells. We have demonstrated previously that inflammatory cytokines increased LDL-C uptake by disrupting LDL receptor feedback regulation in VSMCs and HMCs. [7] [8] [9] 21, 22 In this setting, it is important to understand the roles of HMGCoA-R in foam cell formation, especially under inflammatory stress. To exclude the involvement of scavenger receptor pathways in lipid accumulation in our in vitro studies, we used the antioxidants butylated hydroxytoluene and EDTA in cell culture medium to prevent the oxidation of LDL, which minimized the influence of scavenger receptor-mediated lipid uptake. Therefore, the cholesterol accumulation observed was mainly because of increased uptake through LDL receptor and de novo cholesterol synthesis by HMGCoA-R. In vivo, we used ApoE/SRA/CD36 KO mice as a model, which allowed us to exclude the involvement of scavenger receptors and to investigate the specific roles of LDL receptor and HMGCoA reductase in cholesterol accumulation and plaque formation under inflammatory stress.
We have induced previously a low-grade long-term chronic systemic inflammation characterized by increased serum SAA in ApoE KO mice by a subcutaneous injection of 10% casein, 36, 37 thereby increasing lipid accumulation in the liver 36 and aorta. 7 This model aided the study of the role of inflammatory stress, which is independent of other metabolic disorders caused by chronic renal dysfunction on vascular injury. In this study, we used ApoE/SRA/CD36 KO mice fed a Western diet and subcutaneously injected with casein to induce a predictable low-grade systemic inflammation. We tested whether this inflammatory stress causes foam cell formation by enhancing intracellular cholesterol synthesis and statin resistance in vessels. SAA in mice, like C-reactive protein in man, is an acute-phase protein synthesized by the liver. Our results showed that casein injection significantly increased serum levels of IL-6 and SAA, suggesting a successful induction of chronic systemic inflammation. In the ApoE/SRA/CD36 KO mice model, we demonstrated that inflammatory stress increased lipid accumulation in the aorta of the inflamed animal by increasing the expression of HMGCoA-R activity. High expression of SCAP and nSREBP2 was also observed.
Atorvastatin at a lower dose reduced lipid accumulation in the aorta of noninflamed controls. However, the high levels of HMGCoA-R in inflamed mice result in a high rate of tissue cholesterol synthesis, thereby overriding the inhibitory effect of statins on HMGCoA-R activity and causing statin resistance in the aorta. This weakens the plasma lipid-lowering effect of atorvastatin at a lower dose in the inflamed mice, whereas a higher concentration of atorvastatin was required to achieve a similar effect in reducing serum cholesterol level in inflamed group. Such statin resistance might explain why patients with higher C-reactive protein levels are less likely to benefit equally in cardiovascular protection from low-dose statin treatment. 2 Liver LDL receptor plays an important role in maintaining plasma LDL-C level. In physiological conditions, statin increases hepatic LDL receptor levels and lowers plasma LDL-C by inhibiting HMGCoA-R-mediated intracellular cholesterol levels. We demonstrated that LDL receptor on the hepatic cells is more sensitive to upregulation by intracellular cholesterol depletion with statin treatment (negative feedback regulation) in comparison with VSMCs ( Figure 6B ). After cholesterol uptake, increased intracellular cholesterol inhibits LDL receptor expression by feedback regulation. However, we have demonstrated previously that LDL receptors on the hepatic cells are less prone to downregulation by intracellular cholesterol overloading and easily upregulated by cholesterol depletion with statin treatment in comparison with peripheral cells (tissue-specific regulation). 38 In other words, LDL receptor expression is relatively high in hepatic cells, even in the presence of statin, whereas LDL receptor level in peripheral cells (such as VSMCs) is more sensitive to suppression by intracellular cholesterol. This may be why statins act mainly on hepatic cells because of the tissue-specific regulation.
Furthermore, we have demonstrated previously that inflammatory stress disrupts LDL receptor feedback regulation in both hepatic and peripheral cells by activating SCAP/ SREBP2/LDL receptor pathway that causes LDL-C redistribution from plasma to tissue compartments. This causes lipid accumulation and lowers plasma cholesterol. 7, 36, 39 In this study, we have also shown that inflammation increases LDL receptor expression to a greater degree in HepG2 cells ( Figure I in the online-only Data Supplement) and the liver ( Figure 6A-6C ) than in VSMCs and the aorta. Casein-induced inflammation reduced plasma total cholesterol and LDL levels in mice with increased tissue cholesterol accumulation, suggesting that cholesterol redistribution occurs in inflammatory stress. This may also explain why cholesterol levels are not high in some inflamed patients (such as CKD, diabetes mellitus, and systemic lupus erythematosus), but cardiovascular mortality increased up to 33 to 50× compared with the general population. 40 In this context, increased HMGCoA-R activity in VSMCs, not plasma LDL-C under inflammatory stress, could be a more reliable biomarker for the risk assessment in lipid-lowering treatment. Because of the complexity of tissue specificity in LDL receptor feedback regulation by cholesterol under inflammatory stress, we moved the observation point for statin's effect from LDL receptor to HMGCoA-R/intracellular cholesterol synthesis which is the direct target of statin.
It seems that both statin use and inflammation upregulate hepatic LDL receptors, but do not do so synergistically. The hepatic LDL receptor remains expressed at relatively high levels in the presence of statin and inflammation. This allows the liver to metabolize LDL-C and excrete through the biliary route (plasma LDL-lowering effect), which may explain why prescribing statins to inflamed patients leads to the expected reduction in plasma LDL-C. However, the active HMGCoA-R-mediated cholesterol synthesis in peripheral tissues, such as VSMCs, may cause cholesterol accumulation and foam cell formation through de novo cholesterol synthesis.
Taken together, our in vitro and in vivo data have demonstrated that inflammatory stress increased intracellular cholesterol synthesis by enhancing HMGCoA-R activity. Increased intracellular cholesterol synthesis, together with increased cholesterol uptake and reduced cholesterol efflux previously demonstrated by our group, causes foam cell formation in the aorta. Conventional doses of statins do not prevent continuous activation of cholesterol synthesis by inflammatory stress in peripheral cells and cause statin resistance ( Figure V in the online-only Data Supplement). High expression and abnormal Golgi translocation of SCAP, which disrupts HMGCoA-R feedback regulation, could be the molecular mechanism underlying statin resistance induced by inflammatory stress. A consequence of inflammatory stress is that statin resistance necessitates high concentrations of these drugs to protect peripheral tissues from cholesterol accumulation.
